海外の治験の状況「前立腺癌」での検索結果
167件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
- Castration-Resistant Prostate Cancer br>C04.588.945.440.770 C61;C00-D48;C04.588.945.440.770
- Australia, Brazil, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Norway, Poland, Romania, Russian Federation, South Africa, Switzerland, United Kingdom, United States
- 2011-06-13
- RANDOMIZED, OPEN LABEL MULTI-CENTER STUDY COMPARING CABAZITAXEL AT 20 MG/M² AND AT 25 MG/M² EVERY 3 WEEKS IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINING REGIMEN
- Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Korea North, Netherlands, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, United Kindgdom, United States
- 2011-05-12
Not Recruiting
- Cabazitaxel versus Docetaxel both with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
- metastatic Castration Resistant Prostate cancer br>MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Brazil, Canada, Czech Republic, Denmark, European Union, Finland, Germany, Israel, Italy, Mexico, Peru, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, Turkey
- 2011-01-28
Authorised
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer) br>MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2014-06-05
Not recruiting
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
- Prostate Cancer
- Canada, Peru, United States
- 2007-01-30
Not Recruiting
- A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Brazil, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Korea, Republic of, Mexico, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2012-10-18
Not Recruiting
- A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, Peru, Poland, Puerto Rico, Romania, Russian Federation, Spain, United Kingdom, United States
- 2015-11-12
Not Recruiting
- A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Serbia, Singapore, South Africa, Sweden, Switzerland, Taiwan, Province of China, United Kingdom, United States
- 2015-11-11
Recruiting
- An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- Prostatic Neoplasms
- Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Israel, Korea, Republic of, Netherlands, Russian Federation, Spain, Sweden, Taiwan, United Kingdom, United States
- 2016-08-01
Authorised
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Japan, Korea, Republic of, Netherlands, Norway, Spain, Sweden, Taiwan, United Kingdom, United States
- 2017-01-03